C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
June 20, 2024 08:00 ET
|
Centogene NV
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug...
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
May 31, 2024 16:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease
May 14, 2024 08:30 ET
|
Centogene NV
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued...
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
May 10, 2024 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE Receives Nasdaq Non-Compliance Notice
April 02, 2024 16:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for...
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
February 29, 2024 17:00 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
February 28, 2024 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in...
CENTOGENE Explores Strategic Alternatives
February 28, 2024 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare...
CENTOGENE Announces Voting Results of Extraordinary General Meeting
December 19, 2023 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
December 13, 2023 06:30 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and...